Stop Another Transfer: Recurrent Implantation Failure and the 60% Rule

Recurrent implantation failure means an embryo has not implanted despite transferring the expected number of good-quality embryos for a patient’s age and profile, and current guidance points away from waiting out more unexplained cycles. If you have had repeated failed transfers, the immediate step is a structured, evidence-based evaluation, not another transfer without a clear reason for the last one failing.

TL;DR:

• Most cases of recurrent implantation failure involve multiple factors, including chromosomal abnormalities, uterine issues, immune conditions, and lifestyle factors.
• Testing should be tailored to the patient’s age, embryo quality, and prior results, with common investigations including hysteroscopy, endometrial biopsy, and imaging.
• Identifying and treating conditions like endometritis or uterine polyps through targeted procedures can significantly improve implantation chances.
• Embryo genetic testing (PGT-A) helps prioritize embryos for transfer, especially when maternal age or untested embryos increase aneuploidy risk.
• Proceeding with additional embryo transfers should depend on individualized probability estimates, not fixed transfer counts, to avoid unnecessary delays.

Table of Contents

• How recurrent implantation failure is defined today and why definitions differ
• Main causes of repeated implantation failure, organized by likelihood and treatability
• Evidence-aware investigation checklist: which tests to consider and in what order
• Treatment options tied to diagnostic findings: what to try when a cause is found
• When to investigate further vs continue another embryo transfer
• How Life IVF Center approaches recurrent implantation failure
• Clinical perspective: realistic expectations and key cautions for patients
• Get an evidence-based evaluation for repeated implantation failure
• Sources
• FAQ

How recurrent implantation failure is defined today and why definitions differ

For years, clinics defined recurrent implantation failure (RIF) using a fixed count, often three or more failed transfers of good-quality embryos, or sometimes as few as two. That approach is still common in everyday conversation, but it treats every patient the same regardless of age, embryo quality, or how many embryos were actually transferred. A 42-year-old with untested embryos and a 32-year-old with euploid blastocysts do not carry the same odds, so a flat number misses the point.

Guideline groups have moved toward individualized, probability-based definitions. The ESHRE good practice recommendations frame RIF around a patient’s cumulative predicted chance of implantation, suggesting that further investigation is warranted once that chance reaches around 60% without a resulting pregnancy. The American Society for Reproductive Medicine takes a related but distinct angle: its 2026 committee opinion defines RIF as failed implantation after transferring the estimated number of good-quality blastocysts needed to reach a high cumulative chance of a positive pregnancy test, rather than a rigid transfer count.

Both frameworks share a common thread: embryo quality and age change the calculation entirely.

• A fixed-count definition (two to four failed transfers) is easy to apply but ignores embryo ploidy status and age.
• ESHRE’s cumulative-chance model uses a roughly 60% threshold to flag when further testing makes sense.
• ASRM ties its definition to the number of good-quality blastocysts a patient would need for a high cumulative chance of success.
• Untested embryos carry more uncertainty than embryos confirmed euploid through PGT-A, which affects how quickly a workup should start.

This shift matters for patients because it means the right time to investigate is not the same for everyone. Someone transferring untested embryos at 39 may reach that threshold sooner than someone transferring confirmed euploid embryos at 30.

Main causes of repeated implantation failure, organized by likelihood and treatability

Recurrent implantation failure rarely has one cause. A comprehensive Frontiers review describes it as multifactorial, spanning embryonic, uterine, immunologic, and lifestyle contributors, and the practical task for a clinical team is figuring out which factors are actually present in a given patient rather than treating all of them at once.

Embryonic causes sit at the top of the list. Chromosomal abnormality, or aneuploidy, becomes more common as maternal age rises, and an embryo with the wrong number of chromosomes is far less likely to implant regardless of how healthy the uterine environment looks. This is why age and prior PGT-A results change how a workup proceeds: an untested embryo from an older patient carries more embryonic uncertainty than a confirmed euploid one.

Endometrial receptivity problems come next. The uterine lining has a narrow window of implantation (WOI), and in some patients that window shifts earlier or later than a standard transfer protocol accounts for. Chronic endometritis, a low-grade inflammation of the endometrium often missed on standard biopsy, is a related and treatable contributor that several reviews flag as worth ruling out early.

Uterine structural problems are mechanical rather than biochemical, but they can be just as disruptive. Polyps, submucosal fibroids, intrauterine adhesions, a uterine septum, or a hydrosalpinx (fluid-filled fallopian tube) can all physically interfere with implantation, and most are correctable with a relatively minor surgical procedure once identified.

Immune, hematologic, and male-factor contributions are less consistently implicated but still worth screening for in the right context. Thrombophilia and antiphospholipid antibodies (APLA) are sometimes evaluated, though testing should be selective rather than routine. Male-factor issues beyond a basic semen analysis, including sperm DNA fragmentation, are increasingly discussed as a contributor to implantation failure even when a standard semen analysis looks normal.

Lifestyle and metabolic factors round out the list. Elevated BMI, smoking, and vitamin D deficiency are each associated with poorer implantation outcomes, and they are also the factors most within a patient’s own control to address before or during a workup.

• Embryonic aneuploidy is the leading contributor, and its likelihood rises with maternal age.
• Endometrial receptivity issues, including a displaced window of implantation and chronic endometritis, are common and often treatable.
• Uterine structural abnormalities (polyps, fibroids, adhesions, septa, hydrosalpinx) are mechanical problems correctable by surgery.
• Immune and hematologic factors, along with sperm-related issues, contribute in a smaller subset of cases and require selective testing.
• Lifestyle and metabolic factors, including BMI, smoking, and vitamin D status, are modifiable contributors worth addressing regardless of other findings.

Recent reviews and trials indicate that identifying and treating chronic endometritis with targeted antibiotics can improve subsequent implantation and pregnancy outcomes in selected patients, which is one reason endometrial testing has become a standard early step rather than an afterthought.

Evidence-aware investigation checklist: which tests to consider and in what order

Not every test is worth running on every patient, and ordering them in the wrong sequence wastes time and money without changing management. A practical workup starts broad and narrows based on findings, rather than running every available test at once.

1. Review the full cycle and embryo history. Before any new test, a specialist should examine prior stimulation protocols, embryo grading, PGT-A results if available, and transfer technique, since patterns in this history often point toward a likely cause.
2. Order imaging. A saline infusion sonohysterogram (SIS) or 3D ultrasound checks for polyps, fibroids, adhesions, or a septum that could be interfering mechanically.
3. Proceed to hysteroscopy when imaging suggests a structural finding, since it allows direct visualization and, often, same-session correction.
4. Test for chronic endometritis using endometrial biopsy with CD138 immunohistochemistry and culture. If positive, targeted antibiotics are typically the next step.
5. Consider endometrial receptivity testing (ERA) in selected cases where a displaced window of implantation is suspected, understanding that its predictive value is still debated and it is not recommended as a routine test for every patient.
6. Discuss PGT-A when prior embryos were untested or when maternal age raises the likelihood of aneuploidy, while being clear about its limitations, including the possibility of discarding embryos with mosaic results that could still be viable.
7. Screen for thrombophilia and endocrine issues, including vitamin D and thyroid function, only when clinically indicated rather than as a blanket panel, and refer to hematology if results come back abnormal.

Recent systematic reviews indicate that a practical initial test panel includes hysteroscopy, endometrial CD138 testing, vitamin D and thrombophilia screening when indicated, with antibiotics reserved for confirmed chronic endometritis rather than prescribed empirically.

Pro Tip: Ask your clinic which tests are likely to change your treatment plan before you agree to run them: a test that cannot alter management, however interesting, is not worth the added cost or delay.

Treatment options tied to diagnostic findings: what to try when a cause is found

Treatment should follow diagnosis, not precede it. Guidelines increasingly caution against stacking empiric therapies onto a transfer cycle simply because a prior one failed, since several commonly offered add-ons lack strong trial support.

When chronic endometritis is confirmed by CD138 immunohistochemistry and culture, antibiotics directed at the specific findings are the standard approach, and repeat biopsy after treatment can confirm resolution before the next transfer. Recent reviews and trials indicate that combination protocols diagnosing and treating chronic endometritis alongside other identified issues, sometimes described in the literature as OPTIMUM-style protocols, have shown improved outcomes in select cohorts, though the reviews are clear that larger randomized trials are still needed before this becomes a universal recommendation.

For structural uterine findings, surgical correction is the established treatment: polypectomy for polyps, myomectomy for submucosal fibroids, adhesiolysis for intrauterine scarring, and hysteroscopic septum resection for a septate uterus. These procedures are generally low-risk and address a mechanical problem directly rather than working around it.

PGT-A has a defined role but is not a universal fix. It is most useful when prior transfers used untested embryos and maternal age raises aneuploidy risk, helping prioritize which embryo to transfer next. It does not, however, address endometrial or uterine causes, and mosaic results require careful counseling since some mosaic embryos still result in healthy pregnancies.

A handful of adjuncts are used conditionally rather than routinely:

• Assisted hatching and hyaluronan-enriched transfer media are sometimes used in selected cases, though evidence for broad benefit is mixed.
• ERA-personalized transfer timing is considered for patients with suspected window-of-implantation displacement, with the understanding that its predictive accuracy is still under debate.
• Immunotherapies such as IVIG, intralipids, prednisone, and tacrolimus, along with empiric anticoagulation, are used by some clinics but carry guideline cautions about limited trial evidence.

On that last point, the ESHRE good practice recommendations are direct: interventions like IVIG, routine anticoagulation, and intralipids lack high-quality randomized controlled trial support and are not recommended for routine use outside of a research setting or a carefully selected case with clear rationale.

For patients with severe uterine factor infertility, or those who have experienced repeated failure despite transferring confirmed euploid embryos, a gestational carrier becomes a reasonable option to discuss. Evidence on euploid embryo transfer and gestational carrier outcomes suggests that embryo quality strongly predicts implantation, and a carrier can remove uterine factors from the equation entirely when the embryo itself is not the limiting factor. This path involves significant counseling around legal, financial, and emotional considerations, and is typically reserved for cases where uterine correction is not possible or has already been tried.

When to investigate further vs continue another embryo transfer

Deciding whether to pause for testing or proceed with another transfer comes down to a patient’s individual cumulative predicted chance, not a fixed rule that applies to everyone. ESHRE’s guidance uses roughly 60% cumulative predicted chance as a practical marker: once a patient’s calculated odds of success cross that point without a pregnancy, further investigation is generally warranted. ASRM’s framing works similarly but centers on the number of good-quality blastocysts a patient would need transferred to reach a high cumulative chance in the first place.

• A younger patient with confirmed euploid embryos may reach that threshold only after several transfers, since each embryo carries strong individual odds.
• An older patient transferring untested embryos may reach it much sooner, since each embryo carries more uncertainty.
• Prior euploid transfers that still failed shift the conversation toward endometrial and uterine causes rather than embryo quality.
• Counseling at this stage should include realistic timelines, emotional support, and a clear rationale for either pausing to test or proceeding with an adjusted protocol.

Shared decision-making is the common denominator across both frameworks: the numbers set a general guardrail, but the right choice for a given patient depends on age, embryo supply, finances, and how much uncertainty they are willing to sit with before testing.

How Life IVF Center approaches recurrent implantation failure

An individualized approach to recurrent implantation failure centers on a framework built around each patient’s cycle history, prior embryo data, genetic testing results, and targeted diagnostics rather than a standard protocol applied to everyone. For patients with repeated failed transfers, that typically means a structured review of previous cycles alongside coordination of the tests most likely to change the plan.

Relevant services for recurrent implantation failure include coordination of PGT-A for embryo assessment, the Endometrial Receptivity Assay (ERA) for suspected window-of-implantation issues, hysteroscopy and saline infusion sonohysterogram for uterine evaluation, and endometrial biopsy with CD138 testing for chronic endometritis. For patients where a gestational carrier becomes the appropriate next step, referrals and guidance through that process may be coordinated.

Before a consultation, it helps to gather prior cycle summaries, embryo grading and PGT-A reports if available, and any past hysteroscopy or biopsy results, since a complete history shortens the path to a useful plan.

Clinical perspective: realistic expectations and key cautions for patients

Recurrent implantation failure is genuinely complex, and many patients go on to achieve a pregnancy once a targeted evaluation identifies a treatable cause or a protocol is adjusted based on real findings. The bigger risk is stacking multiple empiric add-ons, immune therapies, extra medications, unproven supplements, onto a cycle without a clear diagnostic reason, since that approach adds cost and delay without matching evidence. A center willing to explain its reasoning, and to say when a test will not change anything, is worth more than one offering every add-on available. Realistic timelines and psychological support matter as much as the medical plan itself.

— Ben

Get an evidence-based evaluation for repeated implantation failure

If you have had more than one failed transfer, the most useful next step is a workup that actually targets a cause rather than another cycle run the same way as the last. Life IVF Center’s Precision IVF® approach builds a plan around your own cycle history, prior embryo results, and targeted testing, instead of a one-size protocol.

Depending on what your history suggests, that might include coordinating genetic testing for embryo assessment, arranging pre-cycle diagnostics through the pre-IVF testing panel (which covers infectious disease screening, karyotype analysis, and the saline infusion sonohysterogram), or reviewing treatment package options if another IVF cycle or embryo transfer is the right next move. Patients weighing embryo banking or a gestational carrier pathway can also review freezing and storage pricing as part of that planning.

• Bring prior cycle summaries, embryo grading, and any PGT-A or biopsy results to your first visit.
• Ask which tests are likely to change your specific treatment plan before agreeing to them.
• Review pricing pages ahead of time so cost is not a surprise mid-conversation.

To start, book a consultation and bring your records so the visit can focus on next steps rather than gathering history from scratch.

Sources

• Recurrent implantation failure: a committee opinion (2026) | American Society for Reproductive Medicine
• Recurrent implantation failure: A comprehensive summary from etiology to treatment | Frontiers in Endocrinology
• Evidence reviews on implantation failure and tests/treatments (2024) | PMC

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

How to fix recurrent implantation failure?

There is no single fix, since the right treatment depends on the cause identified through testing. Once a specific factor is found, such as chronic endometritis, a uterine polyp, or embryo aneuploidy, treatment is directed at that finding, whether through targeted antibiotics, surgical correction, or reconsidering embryo selection with PGT-A.

Can stress affect embryo implantation?

Stress is a common concern during fertility treatment, but current guidance does not identify it as a primary, independently treatable cause of recurrent implantation failure the way embryonic or uterine factors are. Emotional support and realistic pacing through a workup are still worth prioritizing, since the process itself can be demanding regardless of its direct biological effect.

What does a failed egg implanted look like?

A failed implantation typically shows no physical signs at all, and most patients only learn it did not occur through a negative pregnancy test or bloodwork after a transfer. There is no visible or felt indication that distinguishes a failed cycle from one that simply has not yet resulted in a detectable pregnancy.

Why does IVF fail again and again?

Repeated IVF failure usually traces back to one or more of a few categories: embryo chromosomal abnormality, an endometrium that is not receptive at the time of transfer, uterine structural issues, or less commonly, immune or hematologic factors. Guidelines from ASRM and ESHRE recommend a structured evaluation to identify which of these applies before continuing with additional cycles.

This article is for general educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Fertility care is highly individual; please consult a qualified healthcare professional about your specific circumstances.